{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-234487","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2024-10-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.061410+00:00","generated_at":"2026-05-30T18:03:09.324494+00:00","sec_items":["2.01","3.02","9.01","3.03","5.01","5.02","5.03","5.05","5.06","7.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"OnKure completes reverse merger with Reneo; trades as OKUR with $65M PIPE","bullets":["Reneo acquired OnKure in reverse merger; each OnKure common share exchanged for 0.023596 Class A shares.","PIPE investors subscribed for $65M, receiving 2,839,005 Class A shares; total Class A outstanding ~12.65M.","Reverse stock split 1:10, name change to OnKure Therapeutics, ticker changes from RPHM to OKUR.","Lead candidate OKI-219 (PI3Kα H1047R inhibitor) in Phase 1; early data expected Q4 2024.","New board and management: Nicholas Saccomano CEO, Samuel Agresta CMO, Jason Leverone CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-234487","json":"https://secwatch.observer/filing/0001193125-24-234487.json","markdown":"https://secwatch.observer/filing/0001193125-24-234487.md","text":"https://secwatch.observer/filing/0001193125-24-234487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/d836681d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T18:03:09.324494+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"01b06402d4","claim":"Isaac Manke was appointed as Class I Director at OnKure Therapeutics, Inc..","evidence_excerpt":"Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}]},{"claim_id":"63ff7dd157","claim":"Andrew Phillips was appointed as Chair of the Board at OnKure Therapeutics, Inc..","evidence_excerpt":"Also on October 4, 2024, Andrew Phillips, Ph.D. was appointed as the Chair of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chair of the Board"}]},{"claim_id":"a659d4c982","claim":"Edward T. Mathers was appointed as Class II Director at OnKure Therapeutics, Inc..","evidence_excerpt":"Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}]},{"claim_id":"a76135e34c","claim":"Nicholas Saccomano was appointed as Class I Director at OnKure Therapeutics, Inc..","evidence_excerpt":"Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}]},{"claim_id":"a80378c5e3","claim":"Andrew Phillips was appointed as Class III Director at OnKure Therapeutics, Inc..","evidence_excerpt":"Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}]},{"claim_id":"c5d8145dca","claim":"R. Michael Carruthers was appointed as Class II Director at OnKure Therapeutics, Inc..","evidence_excerpt":"Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}]},{"claim_id":"daec546b9b","claim":"Valerie M. Jansen was appointed as Class II Director at OnKure Therapeutics, Inc..","evidence_excerpt":"Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}]},{"claim_id":"f8c7f29f15","claim":"Michael Grey was appointed as Class III Director at OnKure Therapeutics, Inc..","evidence_excerpt":"Effective as of the Effective Time, Nicholas Saccomano and Isaac Manke were appointed as Class I directors, R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers were appointed as Class II directors and Andrew Phillips and Michael Grey were appointed as Class III directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/0001193125-24-234487-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}